Operations and Assets for Operating Segments and Geographic Information |
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows: | | | | | | | | | | For the three months ended March 31, | (In thousands) | 2016 | | 2015 | Revenue from services: | | | | Pharmaceutical | $ | — |
| | $ | — |
| Diagnostics | 252,522 |
| | 2,009 |
| Corporate | — |
| | 60 |
| | $ | 252,522 |
| | $ | 2,069 |
| Product revenues: | | | | Pharmaceutical | $ | 19,899 |
| | $ | 15,486 |
| Diagnostics | — |
| | — |
| Corporate | — |
| | — |
| | $ | 19,899 |
| | $ | 15,486 |
| Revenue from transfer of intellectual property: | | | | Pharmaceutical | $ | 18,616 |
| | $ | 12,529 |
| Diagnostics | — |
| | — |
| Corporate | — |
| | — |
| | $ | 18,616 |
| | $ | 12,529 |
| Operating (loss) income: | | | | Pharmaceutical | $ | (1,330 | ) | | $ | (37,924 | ) | Diagnostics | (2,355 | ) | | (8,477 | ) | Corporate | (23,833 | ) | | (9,979 | ) | Less: Operating loss attributable to noncontrolling interests | — |
| | (534 | ) | | $ | (27,518 | ) | | $ | (56,914 | ) | Depreciation and amortization: | | | | Pharmaceutical | $ | 2,861 |
| | $ | 1,756 |
| Diagnostics | 19,320 |
| | 1,747 |
| Corporate | 18 |
| | 22 |
| | $ | 22,199 |
| | $ | 3,525 |
| Net loss from investment in investees: | | | | Pharmaceutical | $ | (2,050 | ) | | $ | (1,761 | ) | Diagnostics | (295 | ) | | — |
| Corporate | — |
| | — |
| | $ | (2,345 | ) | | $ | (1,761 | ) | Revenues: | | | | United States | $ | 252,438 |
| | $ | 2,493 |
| Ireland | 22,144 |
| | 12,104 |
| Chile | 6,983 |
| | 6,452 |
| Spain | 4,023 |
| | 3,937 |
| Israel | 4,743 |
| | 4,213 |
| Mexico | 706 |
| | 885 |
| | $ | 291,037 |
| | $ | 30,084 |
|
| | | | | | | | | (In thousands) | March 31, 2016 | | December 31, 2015 | Assets: | | | | Pharmaceutical | $ | 1,246,467 |
| | $ | 1,234,752 |
| Diagnostics | 1,435,297 |
| | 1,421,034 |
| Corporate | 111,442 |
| | 143,402 |
| | $ | 2,793,206 |
| | $ | 2,799,188 |
| Goodwill: |
| |
| Pharmaceutical | $ | 255,159 |
| | $ | 251,225 |
| Diagnostics | 491,802 |
| | 492,123 |
| Corporate | — |
| | — |
| | $ | 746,961 |
| | $ | 743,348 |
|
|